References:
1. Beltran BE, Paredes S, Castro D, Cotrina E, Sotomayor EM, Castillo
JJ. High red cell distribution width is an adverse predictive and
prognostic factor in patients with diffuse large B-Cell lymphoma treated
with chemoimmunotherapy. Clinical Lymphoma Myeloma and Leukemia.
2019;19(9):e551-e7.
2. Coiffier B, Lepage E, Brière J, Herbrecht R, Tilly H, Bouabdallah R,
et al. CHOP chemotherapy plus rituximab compared with CHOP alone in
elderly patients with diffuse large-B-cell lymphoma. New England Journal
of Medicine. 2002;346(4):235-42.
3. Martelli M, Ferreri AJ, Agostinelli C, Di Rocco A, Pfreundschuh M,
Pileri SA. Diffuse large B-cell lymphoma. Critical reviews in
oncology/hematology. 2013;87(2):146-71.
4. Friedberg JW. New Strategies in Diffuse Large B-cell Lymphoma:
Translating Findings from Gene Expression Analyses into Clinical
PracticeDLBCL Gene Expression Profiling. Clinical Cancer Research.
2011;17(19):6112-7.
5. Vaidya R, Witzig T. Prognostic factors for diffuse large B-cell
lymphoma in the R (X) CHOP era. Annals of oncology. 2014;25(11):2124-33.
6. Bento L, Díaz‐López A, Barranco G, Martín‐Moreno AM, Baile M, Martín
A, et al. New prognosis score including absolute lymphocyte/monocyte
ratio, red blood cell distribution width and beta‐2 microglobulin in
patients with diffuse large B‐cell lymphoma treated with R‐CHOP: Spanish
Lymphoma Group Experience (GELTAMO). British journal of haematology.
2020;188(6):888-97.
7. Chen H, Zhong Q, Zhou Y, Qin Y, Yang J, Liu P, et al. Enhancement of
the International prognostic index with β2-microglobulin, platelet count
and red blood cell distribution width: a new prognostic model for
diffuse large B-cell lymphoma in the rituximab era. BMC cancer.
2022;22(1):583.
8. Li Z-M, Huang J-J, Xia Y, Sun J, Huang Y, Wang Y, et al. Blood
lymphocyte-to-monocyte ratio identifies high-risk patients in diffuse
large B-cell lymphoma treated with R-CHOP. PloS one. 2012;7(7):e41658.
9. Wang J, Zhou X, Liu Y, Li Z, Li X. Prognostic significance of
neutrophil-to-lymphocyte ratio in diffuse large B-cell lymphoma: A
meta-analysis. PLoS One. 2017;12(4):e0176008.
10. Förhécz Z, Gombos T, Borgulya G, Pozsonyi Z, Prohászka Z, Jánoskuti
L. Red cell distribution width in heart failure: prediction of clinical
events and relationship with markers of ineffective erythropoiesis,
inflammation, renal function, and nutritional state. American heart
journal. 2009;158(4):659-66.
11. Jo YH, Kim K, Lee JH, Kang C, Kim T, Park H-M, et al. Red cell
distribution width is a prognostic factor in severe sepsis and septic
shock. The American journal of emergency medicine. 2013;31(3):545-8.
12. Lee WS, Kim T-Y. Relation between red blood cell distribution width
and inflammatory biomarkers in rheumatoid arthritis. Archives of
pathology & laboratory medicine. 2010;134(4):505-6.
13. Lippi G, Targher G, Montagnana M, Salvagno GL, Zoppini G, Guidi GC.
Relation between red blood cell distribution width and inflammatory
biomarkers in a large cohort of unselected outpatients. Archives of
pathology & laboratory medicine. 2009;133(4):628-32.
14. Bick RL, Baker WF. Diagnostic efficacy of the D-dimer assay in
disseminated intravascular coagulation (DIC). Thrombosis research.
1992;65(6):785-90.
15. Fronas S, Wik HS, Dahm AEA, Jørgensen CT, Gleditsch J, Raouf N, et
al. Safety of D‐dimer testing as a stand‐alone test for the exclusion of
deep vein thrombosis as compared with other strategies. Journal of
Thrombosis and Haemostasis. 2018;16(12):2471-81.
16. Liu B, Li B, Zhou P, Yue W, Wang T, Wang J, et al. Prognostic value
of pretreatment plasma D-dimer levels in patients with diffuse large B
cell lymphoma (DLBCL). Clinica Chimica Acta. 2018;482:191-8.
17. Puurunen MK, Enserro D, Xanthakis V, Larson MG, Benjamin EJ, Tofler
GH, et al. Biomarkers for the prediction of venous thromboembolism in
the community. Thrombosis Research. 2016;145:34-9.
18. Rowbotham B, Whitaker A, Masci P. Plasma cross-linked fibrin
degradation product (XLFbDP) assays in an in vivo model of fibrinolysis.
Blood coagulation & fibrinolysis: an international journal in
haemostasis and thrombosis. 1990;1(6):653-61.
19. Geng Y-d, Chen Y-r, Jin J, Wang X-d, Zhang S, Li D-j. Prognostic
value of D-dimer in patients with diffuse large B-cell lymphoma: a
retrospective study. Current Medical Science. 2019;39:222-7.
20. Desch A, Gebhardt C, Utikal J, Schneider SW. D‐dimers in malignant
melanoma: Association with prognosis and dynamic variation in disease
progress. International Journal of Cancer. 2017;140(4):914-21.
21. Takeuchi H, Abe M, Takumi Y, Hashimoto T, Miyawaki M, Okamoto T, et
al. Elevated red cell distribution width to platelet count ratio
predicts poor prognosis in patients with breast cancer. Scientific
reports. 2019;9(1):1-7.
22. Yao D, Wang Z, Cai H, Li Y, Li B. Relationship between red cell
distribution width and prognosis in patients with breast cancer after
operation: a retrospective cohort study. Bioscience Reports. 2019;39(7).
23. Koma Y, Onishi A, Matsuoka H, Oda N, Yokota N, Matsumoto Y, et al.
Increased red blood cell distribution width associates with cancer stage
and prognosis in patients with lung cancer. PloS one. 2013;8(11):e80240.
24. Wang Y, Zhou Y, Zhou K, Li J, Che G. Prognostic value of
pre-treatment red blood cell distribution width in lung cancer: a
meta-analysis. Biomarkers. 2020;25(3):241-7.
25. Ai L, Mu S, Hu Y. Prognostic role of RDW in hematological
malignancies: a systematic review and meta-analysis. Cancer cell
international. 2018;18:1-8.
26. Geng Y, Jian C, Yang S, Wu S, Zhou J, Li D. The prognostic value of
d-dimer in de novo acute myeloid leukemia. The American Journal of the
Medical Sciences. 2016;352(2):129-33.
27. Herraez I, Bento L, Del Campo R, Sas A, Ramos R, Ibarra J, et al.
Prognostic role of the red blood cell distribution width (RDW) in
Hodgkin lymphoma. Cancers. 2020;12(11):3262.
28. Albayrak S, Zengin K, Tanik S, Bakirtas H, Imamoglu A, Gurdal M. Red
cell distribution width as a predictor of prostate cancer progression.
Asian Pacific Journal of Cancer Prevention. 2014;15(18):7781-4.
29. Feng J-F, Yang X, Chen S, Zhao Q, Chen Q-X. Prognostic value of
plasma D-dimer in patients with resectable esophageal squamous cell
carcinoma in China. Journal of Cancer. 2016;7(12):1663.
30. Han F, Liu Y, Cheng S, Sun Z, Sheng C, Sun X, et al. Diagnosis and
survival values of neutrophil-lymphocyte ratio (NLR) and red blood cell
distribution width (RDW) in esophageal cancer. Clinica Chimica Acta.
2019;488:150-8.
31. Wang P-F, Song S-Y, Guo H, Wang T-J, Liu N, Yan C-X. Prognostic role
of pretreatment red blood cell distribution width in patients with
cancer: A meta-analysis of 49 studies. Journal of Cancer.
2019;10(18):4305.
32. Yuksel C, Ersen O, Cuclu S, Bakırarar B, Ünal A, Demirci S.
Prognostic role of red distribution width (RDW) value in gastric cancer.
Journal of the College of Physicians and Surgeons Pakistan. 2021;31(1).
33. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D,
et al. Meta-analysis of observational studies in epidemiology: a
proposal for reporting. Jama. 2000;283(15):2008-12.
34. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis
JP, et al. The PRISMA statement for reporting systematic reviews and
meta-analyses of studies that evaluate health care interventions:
explanation and elaboration. Journal of clinical epidemiology.
2009;62(10):e1-e34.
35. Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa scale
(NOS) for assessing the quality of nonrandomised studies in
meta-analyses. Ottawa: Ottawa Hospital Research Institute.
2011;2(1):1-12.
36. Duan S, Zhang Y, Xu S, Jiang P, Qi Q. Contrast-Enhanced Ultrasound
Parameters and D-Dimer: New Prognostic Parameters for Diffuse Large
B-Cell Lymphoma. Cancer Management and Research. 2022:2535-44.
37. Hasan KM, Elmeshhedany AY. Prognostic value of absolute
lymphocyte/monocyte ratio, red cell distribution width and
neutrophil/lymphocyte ratio in diffuse large B-cell lymphoma patients.
Cellular and Molecular Biology. 2021;67(3):61-8.
38. Huang H, Fan L, Fu D, Lin Q, Shen J. High pretreatment plasma
D-dimer levels predict poor survival in patients with diffuse large
B-cell lymphoma in the real world. Translational Cancer Research.
2021;10(4):1723.
39. Li D, Li S, Xia Z, Cao J, Zhang J, Chen B, et al. Prognostic
significance of pretreatment red blood cell distribution width in
primary diffuse large B-cell lymphoma of the central nervous system for
3P medical approaches in multiple cohorts. EPMA Journal.
2022;13(3):499-517.
40. Li M, Xia H, Zheng H, Li Y, Liu J, Hu L, et al. Red blood cell
distribution width and platelet counts are independent prognostic
factors and improve the predictive ability of IPI score in diffuse large
B-cell lymphoma patients. BMC cancer. 2019;19:1-11.
41. Periša V, Zibar L, Sinčić-Petričević J, Knezović A, Periša I, Barbić
J. Red blood cell distribution width as a simple negative prognostic
factor in patients with diffuse large B-cell lymphoma: a retrospective
study. Croatian medical journal. 2015;56(4):334-43.
42. Tanaka A, Shimomura Y, Yabushita T, Ishikawa T. High Pretreatment
Plasma D-Dimer Levels Are Associated with Poor Prognosis in Patients
with Newly Diagnosed Diffuse Large B-Cell Lymphomas Treated with
Immunochemotherapy. Blood. 2018;132:4219.
43. Zhou S, Fang F, Chen H, Zhang W, Chen Y, Shi Y, et al. Prognostic
significance of the red blood cell distribution width in diffuse large
B-cell lymphoma patients. Oncotarget. 2017;8(25):40724.
44. Riedl J, Posch F, Königsbrügge O, Lötsch F, Reitter E-M, Eigenbauer
E, et al. Red cell distribution width and other red blood cell
parameters in patients with cancer: association with risk of venous
thromboembolism and mortality. PloS one. 2014;9(10):e111440.
45. Yilmaz A, Malya F, Ozturk G, Çitgez B, Ozdenkaya Y, Ersavas C, et
al. Effect of pre-operative red blood cell distribution on cancer stage
and morbidity rate in patients with pancreatic cancer. International
journal of clinical and experimental medicine. 2014;7(9):3072.
46. Iriyama N, Hatta Y, Kobayashi S, Uchino Y, Miura K, Kurita D, et al.
Higher red blood cell distribution width is an adverse prognostic factor
in chronic-phase chronic myeloid leukemia patients treated with tyrosine
kinase inhibitors. Anticancer Research. 2015;35(10):5473-8.
47. Podhorecka M, Halicka D, Szymczyk A, Macheta A, Chocholska S, Hus M,
et al. Assessment of red blood cell distribution width as a prognostic
marker in chronic lymphocytic leukemia. Oncotarget. 2016;7(22):32846.
48. Luo H, Quan X, Song X-Y, Zhang L, Yin Y, He Q, et al. Red blood cell
distribution width as a predictor of survival in nasal-type, extranodal
natural killer/T-cell lymphoma. Oncotarget. 2017;8(54):92522.
49. Wang J, Xie X, Cheng F, Zhou X, Xia J, Qian X, et al. Evaluation of
pretreatment red cell distribution width in patients with multiple
myeloma. Cancer Biomarkers. 2017;20(3):267-72.
50. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related
inflammation. nature. 2008;454(7203):436-44.
51. Demirkol S, Balta S, Cakar M, Unlu M, Arslan Z, Kucuk U. Red cell
distribution width: A novel infl ammatory marker in clinical practice.
Cardiology Journal. 2013;20(2):209-.
52. Macciò A, Madeddu C, Gramignano G, Mulas C, Tanca L, Cherchi MC, et
al. The role of inflammation, iron, and nutritional status in
cancer-related anemia: results of a large, prospective, observational
study. haematologica. 2015;100(1):124.
53. Ay C, Dunkler D, Pirker R, Thaler J, Quehenberger P, Wagner O, et
al. High D-dimer levels are associated with poor prognosis in cancer
patients. haematologica. 2012;97(8):1158-64.
54. Dirix LY, Salgado R, Weytjens R, Colpaert C, Benoy I, Huget P, et
al. Plasma fibrin D-dimer levels correlate with tumour volume,
progression rate and survival in patients with metastatic breast cancer.
British journal of cancer. 2002;86(3):389-95.
55. Oya M, Akiyama Y, Okuyama T, Ishikawa H. High preoperative plasma
D-dimer level is associated with advanced tumor stage and short survival
after curative resection in patients with colorectal cancer. Japanese
journal of clinical oncology. 2001;31(8):388-94.